However, approaches combining HER2-targeted therapies with immune checkpoint inhibitors or other immunomodulatory agents are being explored in clinical trials to enhance antitumor immune responses and improve outcomes for patients with HER2-positive breast cancer [90]. This evidence concerns the gene ERBB2 and breast carcinoma.